Pitavastatin was associated with reductions in noncalcified plaque volume and progression among patients with HIV infection at low to moderate risk for CVD.
Pitavastatin was associated with reductions in noncalcified plaque volume and progression among patients with HIV infection at low to moderate risk for CVD.
Pitavastatin was associated with reductions in noncalcified plaque volume and progression among patients with HIV infection at low to moderate risk for CVD.